GCP ClinPlus

GCP ClinPlus: Your Premier Partner for Clinical Research in China: GCP ClinPlus is a leading Contract Research Organization based in the US and China with a proven track record of excellence in clinical research and regulatory success. As China emerges as a critical market for global pharmaceutical development, we serve as the ideal bridge between international sponsors and China's vast research opportunities while also serving biometrics needs worldwide. Our Achievements: - Pioneering Approvals: Successfully conducted clinical studies for China's first approved stem cell therapy and first gene therapy for thalassemia - Extensive Experience: Served 460+ clients across 2,000+ clinical projects - Regulatory Success: Secured 200 NDA approvals from FDA, EMA & NMPA - Therapeutic Expertise: Specialized in oncology, endocrinology, rare diseases, ophthalmology, gene/cell therapy, and dermatology - Nationwide Access: Connected to 1,300+ GCP-compliant clinical research sites throughout China Why Partner With GCP ClinPlus: - Strategic Advantages - Access to China's large treatment-naïve patient population - Navigate NMPA's accelerated drug approval pathways - Leverage significant cost efficiencies (30-40% lower than US/Europe) - Benefit from faster patient recruitment timelines - Flexible Partnership Models: - Full-Service CRO: End-to-end clinical trial management in China - Regulatory Consultation: Expert guidance on China-specific requirements - Functional Service Provider (FSP): Seamless extension of your team in China GCP ClinPlus combines local expertise with international standards, enabling global sponsors and CROs to confidently expand their clinical research into China while maintaining quality, compliance, and efficiency.